Atossa Therapeutics (ATOS) Share-based Compensation (2011 - 2026)
Atossa Therapeutics (ATOS) posted quarterly Share-based Compensation of $2.3 million for Q1 2026, up 308.53% year-over-year from $563000.0 in Q1 2025, and down 13.08% quarter-over-quarter from $2.6 million in Q4 2025.
Atossa Therapeutics (ATOS) Share-based Compensation (2011 - 2026) Analysis & Trends
Atossa Therapeutics (ATOS) has reported Share-based Compensation for 16 consecutive years, with $2.3 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Share-based Compensation rose 308.53% year-over-year to $2.3 million; the TTM figure through Mar 2026 stood at $2.3 million (down 37.55% YoY), while the FY2025 annual figure was $2.6 million, down 11.8% from the prior year.
- Share-based Compensation retreated to $2.3 million in Q1 2026 per ATOS's latest filing, from $2.6 million in the prior quarter.
- Across five years, Share-based Compensation topped out at $3.0 million in Q3 2025 and bottomed at $352000.0 in Q2 2024.
- Historically, Share-based Compensation has averaged $1.4 million across 5 years, with a median of $1.6 million in 2023.
- Annual changes were most pronounced in 2024 — Share-based Compensation tumbled 78.04% — and 2026, when it surged 308.53%.
- Atossa Therapeutics' Share-based Compensation stood at $1.5 million in 2022, then sank by 66.41% to $519000.0 in 2023, then surged by 289.02% to $2.0 million in 2024, then surged by 31.05% to $2.6 million in 2025, then declined by 13.08% to $2.3 million in 2026.
- Business Quant data shows ATOS's Share-based Compensation at $2.3 million in Q1 2026, $2.6 million in Q4 2025, and $3.0 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Stock Comp. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 140.22 Bn | 132.37 Bn | 2.84 Bn | 108.10 Mn |
| 2 | Regeneron Pharmaceuticals | 86.29 Bn | 78.30 Bn | 3.93 Bn | 243.00 Mn |
| 3 | Argenx Se | 65.17 Bn | 59.98 Bn | 1.37 Bn | - |
| 4 | Moderna | 61.38 Bn | 56.24 Bn | 52.00 Mn | 120.00 Mn |
| 5 | BeOne Medicines | 42.18 Bn | 37.09 Bn | 1.53 Bn | 137.41 Mn |
| 6 | Alnylam Pharmaceuticals | 30.99 Bn | 27.68 Bn | 992.69 Mn | 86.63 Mn |
| 7 | BioNTech SE | 28.45 Bn | 10.05 Bn | 668.28 Mn | 28.05 Mn |
| 8 | Insmed | 27.47 Bn | 26.31 Bn | 358.27 Mn | 41.25 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | - |
| 10 | Atossa Therapeutics | 23.12 Mn | 23.12 Mn | - | 815,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 815,000.00 |
| Jun 30, 2026 | 815,000.00 |
| Mar 31, 2026 | 2.30 Mn |
| Mar 31, 2026 | 2.30 Mn |
| Dec 31, 2025 | 2.65 Mn |
| Dec 31, 2025 | 2.65 Mn |
| Sep 30, 2025 | 3.00 Mn |
| Sep 30, 2025 | 3.00 Mn |
| Jun 30, 2025 | 796,000.00 |
| Jun 30, 2025 | 796,000.00 |
| Mar 31, 2025 | 563,000.00 |
| Mar 31, 2025 | 563,000.00 |
| Dec 31, 2024 | 2.02 Mn |
| Dec 31, 2024 | 2.02 Mn |
| Sep 30, 2024 | 749,000.00 |
| Sep 30, 2024 | 749,000.00 |
| Jun 30, 2024 | 352,000.00 |
| Jun 30, 2024 | 352,000.00 |
| Mar 31, 2024 | 417,000.00 |
| Mar 31, 2024 | 417,000.00 |